| Literature DB >> 32915159 |
François-Emery Cotté1, Paméla Voillot2, Bryan Bennett3, Bruno Falissard4,5,6,7, Christophe Tzourio8,9, Pierre Foulquié2, Anne-Françoise Gaudin1, Hervé Lemasson1, Valentine Grumberg10, Laura McDonald11, Carole Faviez2, Stéphane Schück2.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly used to treat several types of tumors. Impact of this emerging therapy on patients' health-related quality of life (HRQoL) is usually collected in clinical trials through standard questionnaires. However, this might not fully reflect HRQoL of patients under real-world conditions. In parallel, users' narratives from social media represent a potential new source of research concerning HRQoL.Entities:
Keywords: health-related quality of life; immunotherapy; measures; patients with cancer; real world; social media use
Mesh:
Substances:
Year: 2020 PMID: 32915159 PMCID: PMC7519426 DOI: 10.2196/19694
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Diagram of the steps for creating the analysis corpus.
Patients characteristics.
| Characteristics | Patients mentioning their quality of life (N=150) | ||
|
|
| ||
|
| Women | 82 (54.7) | |
|
| Men | 60 (40.0) | |
|
| Undetermined | 8 (5.3) | |
|
|
| ||
|
| Lung cancer | 46 (30.7) | |
|
| Melanoma | 41 (27.3) | |
|
| Others | 36 (24.0) | |
|
| Undetermined | 27 (18.0) | |
|
|
| ||
|
| Nivolumab | 31 (20.7) | |
|
| Ipilimumab | 20 (13.3) | |
|
| Pembrolizumab | 16 (10.7) | |
|
| Others | 11 (7.3) | |
|
| Undetermined | 72 (48.0) | |
|
| 267 | ||
|
| Per patient, median (min-max) | 2 (1-11) | |
|
|
| ||
|
| Doctissimo | 43 (28.7) | |
|
| La ligue contre le cancer | 43 (28.7) | |
|
| 16 (10.7) | ||
|
| Others | 48 (32.0) | |
Figure 2Venn diagram showing the distribution of patients according to their posts mentioning HRQoL domains. HRQoL: health-related quality of life.
Verbatim examples of posts related to HRQoLa of patients with cancer.
| HRQoL domain and specific subdomain | Verbatim example (translation from French) |
| ||
|
|
|
| ||
|
| Deteriorated | “Hello, we started immunotherapy 3 weeks ago, we didn’t combine it with [Drug], his health is deteriorating more and more. Yesterday he was re-hospitalized...I don’t think his condition could get any worse...I strongly hope he gets better, that he can eat and move...” | ||
|
|
| |||
|
| Weight loss | “When I was diagnosed with melanoma in May 2010, the [hospital] immediately referred me to the [protocol] ([Drug] treatment). (...) it must be said that I lost 9 kilos after the 1st injection, then 2 kilos per month, until we stopped this treatment, in [month] 2011, for a total weight loss of 28 kilos. Since the beginning of the injections I had to stop working.” | ||
|
|
|
| ||
|
| Optimism | “I have lung cancer and metastasis (...). I have had immuno with [drug] for 69 weeks, I am quite well and the mass sometimes decreases slightly and sometimes I have almost no nodule on the lungs. I have almost no reactions as I do not lose my hair, no nausea, just a little bit. I am at stage 4, but I trust my treatment and I have a lot of hope.” | ||
| Exhaustion | “I have been fighting lung cancer with bone metastases for more than three years. Since the beginning of July, I have been trying immunotherapy. If people have had this treatment, I would like to know what the side effects were. As for me, I am very tired, have no appetite and my moral is deteriorating.” | |||
|
|
|
| ||
|
| Minimal or no physical activity/maintained activity | “Cancer was diagnosed in [month] 2017. An operation was not possible. In [month] after the immunotherapy the saturation level was very low and the oxygen allowed maintaining a very minimal physical activity... a few steps...” | ||
|
|
|
| ||
|
| Normal life | “I have been receiving this treatment for 1 year and a half, I don't know if it will cure me but thanks to [Drug] I have been in remission for more than a year. Relatively non-toxic, it allows to lead a normal life in parallel.” | ||
|
| Reduced activities and pace of life | “Hello. I have melanoma stage 4; for 3 years, interferon, [Drug], [Drug] currently every 15 days. I am tired, so exhausted that I can no longer take care of my house, but I have the rage to live.” | ||
|
|
|
| ||
|
| Maintained work activity | “In short, of course I'm afraid of dying, but that's out of the question. This type of cancer is treatable if taken in time. And I was in stage 4 Clark. Immunotherapy is not always cool, but I still work, I manage the house, the children and I am still smiling.” | ||
|
|
|
| ||
|
| Concentration disorders | “Here I am, dean of this post: a year under [drug]. And no trace of melanoma! (...) If I had to relive it I would stop working earlier because I have the impression that [drug] has mostly prevented me from recovering, from sleeping well, with a cumulative effect on the end where I ended the year on the kneecaps wondering if I was not depressed so much I could not concentrate on anything.” | ||
|
|
|
| ||
|
| No longer participates in family parties | “On the first scan, increased lung metastases...but no new ones, so that's something. (...) We won’t do much for the holidays. Until recently we used to go to my in-laws, there were a lot of us, but since my mother-in-law died and since I'm no longer in Olympic shape, we haven’t been moving around!” | ||
aHRQoL: health-related quality of life.
HRQoLa subdomains in social media posts and their coverage by EORTC QLQ-C30b and FACT-Gc questionnaires.
| HRQoL domains and subdomains in social media (number of occurrences in posts) | EORTC QLQ-C30 coverage (question number) | FACT-G coverage (question number) | |||
|
|
|
| |||
|
| Deteriorated/stable/better (115) | ✓ (Q29) | ✓ (GF7) | ||
|
|
|
| |||
|
| Fatigue/Tiredness (34) | ✓ (Q10, Q12, Q18) | ✓ (GP1) | ||
| None/Unspecified adverse events (23) | X | ✓ (GP5) | |||
| Fever (8) | X | X | |||
| Pain/Joint pain/Leg pain/Liver pain (15) | ✓ (Q9, Q19) | ✓ (GP4) | |||
| Cough (7) | X | X | |||
| Loss of appetite/Weight loss (11) | ✓ (Q13) | X | |||
| Rash/itch (6) | X | X | |||
| Respiratory trouble/Breathlessness (6) | ✓ (Q18) | X | |||
| Headache (3) | X | X | |||
| Thyroid disorders (4) | X | X | |||
| Heavy legs (2) | X | X | |||
| Hair loss (2) | X | X | |||
| Diarrhea (2) | ✓ (Q17) | X | |||
|
|
|
| |||
|
| Optimism/Hope (15) | X | ✓ (GE3) | ||
| Exhaustion (7) | X | X | |||
| Distress (6) | X | X | |||
| Good mental health/Morale (5) | X | ✓ (GE1, GE2) | |||
| Fear (4) | ✓ (Q22) | ✓ (GE5, GE6) | |||
| Depression (3) | ✓ (Q24) | X | |||
| Psychological disorders (3) | X | X | |||
| Stable health (3) | X | X | |||
| Isolate oneself (2) | X | X | |||
| Emotional exhaustion due to side effects (1) | X | X | |||
|
|
|
| |||
|
| Normal life/Reduced activities and pace of life (12) | ✓ (Q6, Q7) | ✓ (GF6, GF3) | ||
| Time constraints regarding medical care (3) | X | X | |||
| Financial problems (2) | ✓ (Q28) | X | |||
| Maintained activities (2) | ✓ (Q6, Q7) | ✓ (GF6) | |||
| Home care constraints (1) | X | X | |||
| Improved HRQoL (1) | ✓ (Q30) | ✓ (GF7) | |||
| Ability to drive again (1) | X | X | |||
|
|
|
| |||
|
| Minimal or no physical activity/maintained activity (6) | ✓ (Q1, Q2, Q3, Q4) | ✓ (GP1, GP7) | ||
| Difficulty walking/eating (5) | ✓ (Q2, Q3, Q5) | X | |||
| Difficulty climbing stairs (1) | ✓ (Q2, Q3, Q5) | X | |||
| Difficulty getting into bed alone (1) | ✓ (Q2, Q3, Q5) | X | |||
|
|
|
| |||
|
| Sick leave (6) | ✓ (Q6) | ✓ (GF1, GF2) | ||
| Maintained work activity (2) | ✓ (Q6) | ✓ (GF1, GF2) | |||
| Reduction in working time (1) | ✓ (Q6) | ✓ (GF1, GF2) | |||
|
|
|
| |||
|
| Concentration problems (1) | ✓ (Q20) | X | ||
| Memory problems (1) | ✓ (Q25) | X | |||
|
|
|
| |||
|
| Requiring family assistance for medical care (1) | ✓ (Q26) | X | ||
| Inability to participate in family celebrations (1) | ✓ (Q26) | X | |||
aHRQoL: health-related quality of life.
bEORTC QLQ-C39: European Organization for Research and Treatment of Cancer QLQ-C30.
cFACT-G: Functional Assessment of Cancer Therapy - General.
Figure 3Diagram indicating the coverage rates of each HRQoL domains retrieved in social media by the standard questionnaires EORTC QLQ-C30 and FACT-G. FACT-G: Functional Assessment of Cancer Therapy - General; QLQ-C30: Quality of Life Questionnaire Core 30.